Skip to main navigation Skip to search Skip to main content

Does Weight Impact Anidulafungin Pharmacokinetics?

  • Vincent J. Lempers
  • , Anne van Rongen
  • , Eric P. van Dongen
  • , Bert van Ramshorst
  • , David M. Burger
  • , Rob E. Aarnoutse
  • , Catherijne A. Knibbe
  • , Roger J. Brüggemann

Research output: Contribution to journalArticlepeer-review

23 Citations (Scopus)

Abstract

Bodyweight has been shown to influence anidulafungin exposure, but data from obese patients are lacking. We determined anidulafungin pharmacokinetics (100-mg single dose) in eight morbidly obese subjects (body mass index >40 kg/m2). Anidulafungin exposure was on average 32.5 % lower compared with the general patient population, suggesting dose increases may be required in this population.

Original languageEnglish
Pages (from-to)1289-1294
Number of pages6
JournalClinical Pharmacokinetics
Volume55
Issue number10
DOIs
Publication statusPublished - 1 Oct 2016
Externally publishedYes

Fingerprint

Dive into the research topics of 'Does Weight Impact Anidulafungin Pharmacokinetics?'. Together they form a unique fingerprint.

Cite this